NIAID Natural History Protocol Template Version 1.0  
January 31, 2008  
 
Childhood Asthma  in Urban Settings  Confidential  Page 1 of 40 
 
URECA V  Protocol Version 30.0 21 January  2021  
URECA  
 
Urban Environment and Childhood Asthma  
 
 
NIAID Protocol Number: ICAC -07 
 
 
Sponsored by:  
[CONTACT_4461] (NIAID)  
 
 
Principal Investigator: [INVESTIGATOR_14407] E. Gern  
 
 
Version Number: 30.0 
Protocol Addendum  
Continuation of URECA Study to Age 17  
 
 
21 January  2021 
  
Childhood  Asthma in Urban Settings  Confidential  Page 3 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  Statement  of Compliance  
This clinical study will be conducted using good clinical practice (GCP), as delineated in 
Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance E6(R2) , and 
according to the criteria specified in this study protocol.  Before study initiat ion, the protocol and 
the informed consent documents will be reviewed and approved by [CONTACT_106505].  Any 
amendments to the protocol or to the consent materials will also be approved by [CONTACT_765934].  
  
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050180] of Abbrevia tions  ................................ ................................ ................................ ....................  7 
Protocol Summary  ................................ ................................ ................................ ......................  8 
Schematic of Study Design  ................................ ................................ ................................ ....... 10 
Key Roles  ................................ ................................ ................................ ................................ . 11 
1 Background Information  and Scientific Rationale  ................................ ............................  12 
 Background Information  ................................ ................................ ..............................  12 
 Rationale  ................................ ................................ ................................ ....................  12 
 Potential Risks and Benefits  ................................ ................................ .......................  14 
1.3.1  Risks of Study Procedures  ................................ ................................ ...................  14 
1.3.2  Potential Benefits  ................................ ................................ ................................ . 15 
2 Study Objectives  ................................ ................................ ................................ ............  16 
 Primary Objective ................................ ................................ ................................ ........  16 
 Secondary Objectives  ................................ ................................ ................................ . 16 
 Exploratory Objectives  ................................ ................................ ................................  16 
3 Study Design  ................................ ................................ ................................ ..................  16 
 Description of the Study Design  ................................ ................................ ..................  16 
 Study Endpoint  ................................ ................................ ................................ ...........  17 
3.2.1  Primary Endpoint  ................................ ................................ ................................ . 17 
3.2.2  Secondary Endpoints  ................................ ................................ ...........................  17 
4 Study Population  ................................ ................................ ................................ ............  17 
 Population Description  ................................ ................................ ................................  17 
 Participant Inclusion Criteria  ................................ ................................ .......................  18 
5 Study Procedures/Evaluations  ................................ ................................ ........................  [ADDRESS_1050181] Analysis for Allergen and Microbial Products  ................................ ...............  18 
5.1.2  Allergen Skin Testing  ................................ ................................ ...........................  19 
5.1.3  Pre/Post Bronchodilator Pulmonary Function Testing  ................................ ..........  19 
5.1.4  Methacholine Challenge  ................................ ................................ ......................  19 
5.1.5  Exhaled Nitric Oxide Measurement  ................................ ................................ ...... 19 
5.1.6  Induced Sputum  ................................ ................................ ................................ ... 19 
5.1.7  Nasal Epi[INVESTIGATOR_765896]  ................................ ................................ ............  20 
5.1.8  Collection of Nasal Lining Fluid  ................................ ................................ ............  20 
5.1.9  Fitness Testing  ................................ ................................ ................................ .... 20 
 Laborato ry Evaluations  ................................ ................................ ...............................  20 
5.2.1  Clinical and Research Laboratory Evaluations and Specimen Collection  .............  20 
5.2.2  Specimen Preparation, Handling and Shippi[INVESTIGATOR_007]  ................................ ....................  21 
 Substudies  ................................ ................................ ................................ ..................  22 
6 Research Use of Stored Human Samples, Specimens or Data  ................................ ...... 22 
 Use of Stored Samples/Data  ................................ ................................ .......................  22 
 Disposition of Stored Samples/Data  ................................ ................................ ............  22 
7 Study Schedule  ................................ ................................ ................................ ..............  22 
 Informed Consent  ................................ ................................ ................................ ....... 23 
Childhood  Asthma in Urban Settings  Confidential  Page 5 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  
 14/15 -Year Clinic Visit A  ................................ ................................ .............................  23 
 14/15 -Year Clinic Visit B  ................................ ................................ .............................  23 
 16/17 -Year Clinic Visit A  ................................ ................................ .............................  23 
 16/[ADDRESS_1050182] of Subjects after Study Termination  ................................ ..........................  25 
8 Assessment of Safety  ................................ ................................ ................................ ..... 25 
 Defini tion of an Adverse Event (AE)  ................................ ................................ ............  25 
 Definition of a Serious Adverse Event (SAE)  ................................ ...............................  25 
 Death Not Related to Study Procedures  ................................ ................................ ..... 26 
 Methods and Timing for Assessing, Recording, Analyzing and Adverse Events  .........  26 
8.4.1  Methods and Timing for Assessment  ................................ ................................ ... 26 
8.4.2  Recording/Documentation ................................ ................................ ....................  27 
8.4.3  Analysis/Management  ................................ ................................ ..........................  27 
 Repo rting Procedures  ................................ ................................ ................................ . 27 
8.5.1  Serious Adverse Event Reporting  ................................ ................................ ........  27 
8.5.2  Adverse Event Reporting  ................................ ................................ .....................  27 
8.5.3 Reporting to the IRB  ................................ ................................ ............................  28 
8.5.4  Reporting Pregnancy  ................................ ................................ ...........................  28 
 Type and Duration of the Follow -up of Participants after Adverse Events  ...................  28 
 Participant Discontinuation  ................................ ................................ ..........................  28 
 Replacement of a Participant Who Discontinues Study Participation  ..........................  28 
9 Clinical Monitoring Structure  ................................ ................................ ...........................  29 
 Site Monitoring Plan  ................................ ................................ ................................ .... 29 
 Safety Monitoring  ................................ ................................ ................................ ........  29 
9.2.1  Medical Monitor Review  ................................ ................................ .......................  29 
9.2.2  DSMB Review  ................................ ................................ ................................ ...... 29 
10 Statistical C onsiderations  ................................ ................................ ...............................  29 
 Overview  ................................ ................................ ................................ .....................  29 
 Endpoints  ................................ ................................ ................................ ....................  30 
10.2.1  Primary End points  ................................ ................................ ...............................  30 
10.2.2  Secondary Endpoints  ................................ ................................ ...........................  30 
 Measures to Minimize Bias  ................................ ................................ .........................  30 
 Analysis Plan  ................................ ................................ ................................ ..............  31 
10.4.1  Primary Analysis of Primary Objective  ................................ ................................ . 31 
10.4.2  Analysis of Secondary Objectives  ................................ ................................ ........  31 
10.4.3  Analysis of Exploratory Endpoints  ................................ ................................ ........  32 
 Sample Size Considerations  ................................ ................................ .......................  33 
11 Quality Control and Quality Assurance  ................................ ................................ ...........  33 
12 Ethics/Protection of Human Subjects  ................................ ................................ ..............  [ADDRESS_1050183] Keepi[INVESTIGATOR_007]  ................................ ................................ ...............  35 
 Data Management Responsibilities  ................................ ................................ .............  35 
 Data Capture Methods  ................................ ................................ ................................  35 
 Types of Data  ................................ ................................ ................................ .............  36 
 Source Documents and Access to Source Data/Documents  ................................ ....... 36 
 Timing/Reports  ................................ ................................ ................................ ...........  36 
 Study Rec ords Retention  ................................ ................................ ............................  36 
14 Publication Policy  ................................ ................................ ................................ ...........  36 
Appendix A: Scientific References  ................................ ................................ ............................  37 
Appendix B: Schedule of Procedures/Evaluations  ................................ ................................ ..... [ADDRESS_1050184] of Abbreviations  
 
ACRN  Asthma Clinical Research Network  
AE Adverse Event/Adverse Experience  
ANOVA  Analysis of Variance  
APIC  Asthma Phenotypes in the Inner City (trial)  
ATS American Thoracic Society  
BIA Bioelectrical Impedance Analysis  
BMI Body Mass Index  
CFR Code of Federal Regulations  
CRF Case Report Form  
CMP  Clinical Monitoring Plan  
DAIT  Division of Allergy, Immunology, and Transplantation  
DMP  Data Management Plan  
DNA  Deoxyribonucleic Acid  
DSMB  Data and Safety Monitoring Board  
eCRF  Electronic Case Report Form  
EDC  Electronic Data Capture  
eNO Exhaled Nitric Oxide  
FDA Food and Drug Administration  
FEV [ADDRESS_1050185]  
LCA Latent Class Analyses  
MDI Metered -Dose Inhaler  
MOP  Manual of Operations  
mRNA  Messenger RNA (ribonucleic acid)  
N Number (typi[INVESTIGATOR_33891])  
NHLBI  National Heart, Lung, and Blood Institute  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
PBMC  Peripheral Blood Mononuclear Cells  
PD 20 Provocative Dose that causes a 20% fall in FEV 1 
PI [Site] Principal Investigator  
[INVESTIGATOR_765897]/Serious Adverse Experience  
 
Childhood  Asthma in Urban Settings  Confidential  Page 8 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  Protocol Summary  
 
Full Title:  Urban Environment and Childhood Asthma  
Short Title:  URECA  
Conducted by:  [CONTACT_765935]:  [INVESTIGATOR_765898], MD  
Sample Size:  N=609 originally enrolled  
Study Population:  Inner -city children at high risk for development of asthma 
due to family history, plus a small sample of inner -city 
children without family history.  
Accrual Period:  N/A – Study participants were accrued from 2005 -2007  
Study Design:  URECA is a longitudinal birth cohort study which is being 
extended to follow study children to age 17 years.  
Study Duration:  Start Date: 1 April 2021  
End Date: 31 December 2024  
Primary Objective:  To determine the wheezing, asthma and atopy 
phenotypes in minority c hildren growing up in poor urban 
neighborhoods as they develop from birth through 
adolescence.  
Secondary Objectives:  1. To longitudinally analyze the development of lung 
function and its relationship to asthma.  
2. To identify which urban exposures (allergens, 
pollutants, microbes, viral infections, stress) from early 
life onward affect the development and natural history 
through adolescence of asthma, allergic rhinitis and 
allergic sensitization.  
3. To determine the a ssociation of pre -pubertal obesity 
and the effect of pubertal changes in adiposity and sex 
hormones on lung growth and asthma onset, 
prevalence and morbidity.  
Childhood  Asthma in Urban Settings  Confidential  Page 9 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  Exploratory Objectives:  1. To provide samples for analysis and outcomes data 
for use in mechanistic  studies to understand 
relationships between environmental exposures, 
changes in immune development, alterations in DNA 
methylation patterns of airway cells, and the 
development of allergic sensitization, allergic rhinitis 
and asthma.  
2. To work collaborative ly with investigators outside of 
the NIAID asthma network on mechanistic or clinical 
studies to test novel hypotheses and to validate, 
compare and contrast findings from URECA with those 
in other cohorts or clinical studies.  
Endpoints:  Incidence and prevalence of asthma and occurrence of 
specific phenotypes of asthma  
 
  
Childhood  Asthma in Urban Settings  Confidential  Page 11 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  Key Roles  
 
PROTOCOL CHAIR – JAMES GERN, MD  
 
 
 
 
 
 
 
 
NIAID MEDICAL MONITOR –  
 
 
 
 
 
 
 
NIAID PROJECT MANAGER –  
 
 
 
 
 
 
 
STATISTICIAN –  
 
 
 
 
 
 
 
  

Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050186] of care for this group of patients.  
[IP_ADDRESS]  Allergy Skin Testing  
Redness , swelling, and itching of the skin are likely to occur during and 1-[ADDRESS_1050187]. A 
medical provider trained in treating anaphylaxis will be available to provide immediate treatment 
in the event that a participant experiences an allergic reaction. Stoppi[INVESTIGATOR_765899] (but not asthma) symptoms worse. Participants will be told they 
can take their m edications if they need them, but the test will need to be rescheduled.  
[IP_ADDRESS]  Blood Collection  
The risks associated with taking blood include possible pain from the stick, as well as bleeding, 
bruising, and infection of the skin. Lightheadedness and fainting ra rely occur during non -fasting 
blood collections, but are more likely during fasting blood collections. To minimize these risks, a 
staff member who is trained to draw blood from children will collect the samples. Additionally, 
investigative sites may apply an analgesic medication such as EMLA® to the skin before the 
blood draw to reduce the pain of the stick. Side effects from this medication include erythema, 
burning, paleness at the skin site, edema, and alterations in temperature. Reactions are mild 
and t ransient. There is a potential for allergic reactions.  
[IP_ADDRESS]  Spi[INVESTIGATOR_765900], which will go away shortly after the test is 
finished. The albuterol that is given during reversibility testing can cause increased heart r ate 
and blood pressure, nausea, headache, and a jittery or nervous feeling. These symptoms 
usually resolve in less than an hour.  
Participants will be asked to withhold their asthma medications for a period of time before the 
procedure depending on the med ication. Withholding of asthma medications before testing may 
cause a worsening of asthma symptoms.  Participants will be informed that they can take their 
asthma medications if needed, and the procedure will be rescheduled. Exact medications to 
Childhood  Asthma in Urban Settings  Confidential  Page 15 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  withhold, length of abstention and procedures are described in the URECA V Manual of 
Operations (MOP) for ICAC -07. 
[IP_ADDRESS]  Methacholine Challenge  
The m ethacholine challenge can cause coughing, chest tightness, shortness of breath, and 
wheezing.  A medication to open the airways (albuterol) will be promptly given to help reverse 
these effects. There is a rare risk that a severe asthma epi[INVESTIGATOR_765901].  A study clinician 
experienced in asthma care will be available should such an epi[INVESTIGATOR_592076].  
Participants will be asked to withhold their asthma medications for a period of time before the 
procedure, depending on the medication. Withholding of asthma medications before testing may 
cause a worsening of asthma symptoms.  Participants will be informed that they can take their 
asthma medications if needed, and the procedure will be rescheduled. Exact medications to 
withhold, length of abstention and procedures are described in the URECA V MOP for ICAC -07. 
[IP_ADDRESS]  Sputum Induction  
Sputum induction may result in wheezing, coughing , or che st tightness. Participants will be pre -
medicated with albuterol in order to minimize this risk. This procedure may cause throat 
irritation. Participants may rinse their mouths or gargle with water after the procedure to reduce 
these symptoms.  Less commonly , nausea, v omiting, and headache can occur.  
[IP_ADDRESS]  Exhaled Nitric Oxide Measurement  
This test may cause dizziness which will go away soon after the test is finished.  
[IP_ADDRESS]  Nasal Epi[INVESTIGATOR_765902], 
transient nosebleed, sneezing, tearing of the eyes, runny nose, and postnasal drip.  
[IP_ADDRESS]  Collection of Nasal Lining Fluid  
The collection of nas al lining fluid  may produce mild, temporary discomfort such as a tickle nose 
and/or tearin g of the eyes .  
[IP_ADDRESS]  Questionnaires  
There is a possibility that participants may find the questions too personal.  Participants may 
refuse to answer any questions that make them feel uncomfortable.  
1.3.[ADDRESS_1050188] environmental control 
measures. The participant’s asthma may or may not improve while in this study.  
Childhood  Asthma in Urban Settings  Confidential  Page 16 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  2 Study Objectives  
 Primary Objective  
The primary objective of the continuation of URECA to age 17 is to determine the wheezing, 
asthma and atopy phenotypes in minority children growing up in poor urban neighborhoods as 
they develop from birth through adolescence.  
 Secondary Objectives  
Secondary objectives are:  
1. To determine whether early life exposure to allergens in the home in the absence of a 
diverse microbiome is associated with sensitization to those allergens and respi[INVESTIGATOR_037] (perennial rhinitis and allergic asthma phenotypes).  
2. To de termine the association of pre -pubertal obesity and the effect of pubertal changes 
in adiposity and sex hormones on lung growth and asthma onset, prevalence and 
morbidity.  
 Exploratory Objectives  
URECA has several exploratory objectives to use data and samp les collected from the study 
participants:  
1. To determine the relationships between DNAm and gene expression in AECs collected 
from URECA children at ages 11 and 15 years, genotypes, and respi[INVESTIGATOR_765903] 17 years.  
2. To identify which u rban exposures (allergens, pollutants, microbes, viral infections, 
stress) from early life onward are associated with AEC DNAm and gene expression 
(ages 11 and 15 years) and respi[INVESTIGATOR_765904] [ADDRESS_1050189] findings from URECA with those in other cohorts or clinical studies.  
3 Study Design  
 Description of the Study Desi gn 
The continuation protocol retains many of the successful features of the ongoing protocol; 
children will continue to be monitored through quarterly phone calls and yearly clinic visits (see 
Appendix B). Interim goals are to maintain a high level of part icipation in study procedures, and 
retain the current subjects to age [ADDRESS_1050190] data on not only the development and 
resolution of asthma but also asthma morbidity and chang es in asthma severity. Finally, in 
school -aged children, we will be able to identify risk factors for the onset of allergic rhinitis and 
the transition in some children from allergic rhinitis to allergic asthma.    
 Study Endpoint  
3.2.1  Primary Endpoint  
The primary outcome of URECA through age 7 was the development of asthma, which was 
determined using an algorithm that evaluated reported physician diagnosis, lung function, 
symptoms, healthcare utilization and medication use. At age 7, 29% of the URECA study 
participants met this definition for asthma .4 We also identified five specific phenotypes based on 
longitudinal trajectories of symptoms, allergen sensitization, and lung function using data 
through age 7 years .5 These trajectories were refined at age 10 y ears, where an additional 
phenotype with high symptoms, high sensitization, and significant lung function deficits was 
found (Altman M et al, under review) .  
Data regarding asthma diagnosis, the frequency and severity of cough and wheezing illnesses, 
healt hcare utilization, and medication use will continue to be collected during each of the 
quarterly telephone calls. Examinations will also be conducted as part of the scheduled study 
visits to age 17 years, and questions about wheezing and asthma will be ask ed at these visits 
as well. All of this information will be recorded into a centralized database for analysis.  
3.2.2  Secondary Endpoints  
A number of secondary outcome variables will also be assessed as follows:  
1. Methacholine responsiveness – this will be ascerta ined at the 14 /15-year time point.  
2. Pulmonary function – pre- and post -bronchodilator spi[INVESTIGATOR_765905] 14/15 and again at age 16/17.   
3. Allergic sensitization – defined as a dichotomous variable (aeroallergen -specific IgE by 
[CONTACT_765936]) or as a continuum (number of positive skin or sIgE tests, sum of 
sIgE values).  
4. Allergic rhinitis – chronic seasonal or perennial rhinitis and corresponding allergen -
specific IgE or skin test.  
4 Study Po pulation  
 Population Description  
To address the primary objectives of the URECA V protocol, all the participants active in the 
URECA IV protocol in early 2021 will be invited to continue under the new protocol into age 17  
years .  
The URECA study is being co nducted at the Johns Hopkins University School of Medicine, 
Baltimore, MD; [LOCATION_011] University School of Medicine, [LOCATION_011], MA; Children’s Hospi[INVESTIGATOR_503968]-Presby[CONTACT_194840], [LOCATION_001], NY; and Washington University School of Medicine, St. Louis, 
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050191] 20% of the population is below the 
federal poverty level. The resulting study populations in Baltimore and St. Lou is are 
predominantly African -American. The populations in [LOCATION_011] and [LOCATION_001] are more evenly 
divided between African -American and Hispanic (Table 2).  
Table 2.  URECA Study Population by [CONTACT_765937] -American  Mixed  Race  White, Asian, 
Other  
Baltimore  2% 90% 4% 4% 
[LOCATION_011]  31% 54% 11% 4% 
[LOCATION_001]  61% 36% 3% 0% 
St. Louis  2% 88% 8% 1% 
Total  21% 70% 7% 3% 
 
The URECA study enrolled 560 inner -city children at high risk for developi[INVESTIGATOR_765906] a parental history of asthma, allergic rhinitis or atopic dermatitis. A 
small comparison sample of 49 babies without allergic family history was also enrolled. Babies 
born at 34 weeks gestation or later were allowed into the study, provided that there was no 
significant respi[INVESTIGATOR_765907], and they were otherwise 
healthy. Infants with other lung diseases such as respi[INVESTIGATOR_1505], 
bronchopulmonary dysplasia and pneumonias were not enrolled due to confounding effects on 
respi[INVESTIGATOR_765908]. Babies of HIV -infected mothers were excluded due to 
immunomodulatory effects of HIV infection, and of anti -retroviral medications such as 
zidovudine (AZT).  
 Participant Inclusion Criteria  
Partic ipants to be included in URECA V are those who are active in the URECA IV protocol at 
approximately age 14 -16. 
5 Study Procedures/Evaluations  
 Clinical Evaluations  
A number of procedures are currently on hold due to the COVID pandemic, and we will maintain 
flexibility in scheduling based on when research restrictions related to the pandemic are lifted. 
For example, if any of the scheduled assessments do not occur at a visit, that assessment can 
be completed at the next visit after restrictions are lifted. The study assessments and 
techniques employed in the original URECA protocol will continue to be followed as described 
below.  
5.1.[ADDRESS_1050192] specimens will be collected at the age 16/[ADDRESS_1050193] sample will be collected from 
the participant ’s bed (defined as the location  where  the participant  sleeps the most) and 
Childhood  Asthma in Urban Settings  Confidential  Page 19 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  bedroom floor. Handling of specimens and laboratory assays will remain th e same as in the 
original protocol.  
5.1.2  Allergen Skin Testing  
Skin testing to a panel of aeroallergens will be performed at the 14/[ADDRESS_1050194].  Skin testing will be done 
by [CONTACT_765938][INVESTIGATOR_106434] (Greer; Lenoir, NC) in accordan ce with 
generally accepted guidelines .[ADDRESS_1050195].  
5.1.3  Pre/Post Bronchodilator Pulmonary Function Testing  
The 14/15 - and 16/17 -year time points  will each include one pre/post bronchodilator testing 
session. After completion of spi[INVESTIGATOR_765909], albuterol via MDI with 
spacer will be administered. Fifteen minutes later the spi[INVESTIGATOR_765910].  
5.1.[ADDRESS_1050196] responsiveness will 
be measured by [CONTACT_765939] a drop in FEV 1 of 20% 
(PD 20) after the administration of increasing concentrations of methacholine using the small 
volume nebulizer -tidal breathing technique. A train ed and certified pulmonary function 
technician will perform the test based on the procedures outlined in the URECA V MOP for 
ICAC -07. These procedures will be used due to the documented safety of the approach in large 
pediatric asthma populations. Provocho line® will be used as the commercial source of 
methacholine, since it is an FDA approved product for children as young as 5 years of age. 
Testing criteria are described in the MOP for ICAC -07 that ensure the quality of the data 
collected and the safety of the study participants.  
5.1.5  Exhaled Nitric Oxide Measurement  
Measurement of eNO will be obtained at two visits, once in the 14/15 -year time point  and once 
in the 16/17 -year time point. The procedure will be conducted  prior to the measurement of 
spi[INVESTIGATOR_038]. Ex haled NO will be measured employing a technique modified after Silkoff et al.7 
and following American Thoracic Socie ty (ATS) guidelines for eNO assessment.8 Nitric oxide 
concentrations will be measured using a commercially -available analyzer and a procedure 
described in detail in the URECA V MOP for ICAC -07. 
5.1.6  Induced Sputum  
Sputum will be induced at the age  16/17-year time point by [CONTACT_765940] (ACRN).9 
Safety monitoring per spi[INVESTIGATOR_765911]. Processing will be  performed according to the URECA V MOP for ICAC -07. Slides 
will be read at a central site for cellular determinations. Residual sputum cells will be processed 
Childhood  Asthma in Urban Settings  Confidential  Page 20 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  to analy ze cell markers and RNA and DNA isolation for expression and epi[INVESTIGATOR_430212]. 
Sputum supernatants will be collected, aliquoted, and stored pending further analysis.  
5.1.7  Nasal Epi[INVESTIGATOR_765912] 14/[ADDRESS_1050197]  the procedure. The inferior turbinate of one nasal 
passage will be sampled to obtain an adequate number of epi[INVESTIGATOR_765913]. The sampled area will be observed for hemostasis. Procedural details and instructions 
for processing th e samples are included in the URECA V MOP for ICAC -07. 
5.1.8  Collection of Nasal Lining Fluid  
Nasal lining fluid will be collected at the age 14/[ADDRESS_1050198] will be used at the 14/15 -year time point  to assess the participant ’s 
level of fitness.[ADDRESS_1050199] pace for six minutes. The number of meters walked is 
measured, as well as the participant ’s pulse and respi[INVESTIGATOR_697]. The participant is asked to rate 
his or her level of fatigue on a visual analogue scale.  
 Laboratory Evaluations  
5.2.1  Clinical and Research Laboratory Evaluations and Specimen 
Collection  
[IP_ADDRESS]  Urine Pregnancy Testing  
All female s who have reached menarche will be required to have a urine pregnancy test prior to 
any procedures that entail any risk, but not prior to a blood draw. Results of all pregnancy tests 
will be given to the participant and/or caretaker following state laws.   
Pregnancy will not result in withdrawal from the study, but will be reported on the appropriate 
CRFs and followed to outcome. Pregnant participants may not participate in some procedures; 
refer to the URECA V MOP for ICAC -07. If the pregnancy results in anything other than a 
normal birth or elective abortion of a healthy fetus, it will be reported as a SAE.  
[IP_ADDRESS]  Urine Collection  
Urine will be collected at the 14/15, and 16/17 -year time points  for measurement of urinary 
cotinine, a marker for tobacco smoke expo sure. A urine sample will be collected following 
procedures described in the URECA V MOP for ICAC -07. 
[IP_ADDRESS]  Blood Collection  
Blood will be collected while participants are active in URECA V to measure serum markers of 
adiposity and systemic inflammation (e.g., l eptin, adiponectin, hsCRP, IL -6, TNF -α), levels of 
Childhood  Asthma in Urban Settings  Confidential  Page 21 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  sex hormones (e.g. estrogen, testosterone), and insulin resistance  (e.g. fasting insulin and 
glucose), as well as total and allergen -specific IgE.  Blood is also used for analysis of 
immunoregulatory mRNA and protein responses as a measurement of individual and 
developmental immunologic patterns. Plasma and serum proteins will also be analyzed, and 
these assays will be performed in a multiplex format whenever possible. In addition, systems 
approaches (e.g. microarray, proteomics, epi[INVESTIGATOR_7009]) will also be used , as these technologies 
are developed to assess global patterns in immunoregulatory factors in the blood or in blood 
cells. Additional analysis may be done for  potential biomarkers related to asthma and  allergies . 
The amount of blood drawn will follow the NIH Guidelines for Limits of Blood Drawn for 
Research Purposes in the Clinical Center (5/2012) . For pediatric patients, no mo re than 5 m L/kg 
may be drawn for research purposes in a  single day, and no mo re than 9.5 m L/kg may be 
drawn ov er any eight-week period. For adults the amount shall not exceed 10.5 mL/kg  or 550 
mL, whichever is smaller, over any eight -week period.  
[IP_ADDRESS]  Nasal Fluid  
Nasal fluids will be analyzed for proteins (e.g. cytokines) or metabolites  using methods as listed 
above.  
[IP_ADDRESS]  Immunologic Studies  
The overall goal of the immunologic studies is to define effects of environmental stimuli on 
immune development, and then identify patterns of immune development that are associated 
with the development of asthma. These studies will be conducted using cells and fluids from 
blood, the upper airway, and possibly urine.  
5.2.2  Specimen Preparation, Handling and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Instructions for Specimen Storage  
Most samples that are collected at the clinical sites will be shipped directly to processing 
laboratories. However, samples that will need to be stored for at least 3 months (specimens of 
DNA, plasma, etc.), as well as specimens that are generated by [CONTACT_765941], will be sent to a central storage facility pending analysis. This facility will 
maintain a computerized inventory of all of the specimens to be analyzed, and will ship the 
specimens to designated laboratories for analysis upon request.  In order to protect subjects, all 
samples are stored and shipped under code so that neither the participant nor their caregivers  
can be identified individually.  
[IP_ADDRESS]  Specimen Shipment  
Instructions for sample preparation, handling, storage, and shippi[INVESTIGATOR_765914] 
V MOP  for ICAC -07.  Principal Investigators will be responsible for knowing about and 
observing all the regulations for classification, packaging and labeling, permits or authorizations, 
and personnel training for shipment of biological and hazardous materials required for t he 
conduct of this study.  
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050200] designed 
extensive collaborative studies with  research groups identified by [CONTACT_765942], including:  
1. Studies to define mechanisms of microbial effects on the risk of allergic diseases and 
asthma (collaboration with the University of [LOCATION_004] San Francisco),  
2. A systems -based analysis to integrate environmental exposures, epi[INVESTIGATOR_765915], gene transcription, immune development and asthma/allergy clinical 
outcomes and biomarkers (collaboration with the Benaroya Research Institute, 
Seattle, WA and the University of Chic ago), and  
3. Analysis of epi[INVESTIGATOR_765916] -specific T 
cells, and relationship to allergen exposure, sensitization, and expression of clinical 
disease (collaboration with the La  Jolla Institute of Allergy and Immuno logy).  
Each substudy or ancillary study involving URECA participants or samples from participants will 
be accompanied by a proposal specifying the objectives of the substudy, the sample 
requirements, and the analytic plan. If additional samples or procedur es not included in the main 
study consent are required for the substudy, an informed consent addendum will need to be 
signed by [CONTACT_2299]’s caretaker/guardian, and the participant will sign an assent form.  
6 Research Use of Stored Human Samples, Specim ens or 
Data  
 Use of Stored Samples/Data  
Extra research samples remaining once the specified analyses are conducted will be stored 
long-term for future research. Participants will be asked to give permission for long -term storage 
and future use during the co nsent process.  
 Disposition of Stored Samples/Data  
Stored samples will be maintained in long -term storage until they are used or until permission is 
obtained from the CAUSE Steering Committee and DAIT/NIH to destroy them.  
[ADDRESS_1050201] designed 
the protocol with increased flexibility in scheduling. This will include two visits in the 14/1 5-year 
time frame, two visits in the 16/17 -year time frame, and one standalone visit for a subset of 
participants. Many procedures that cannot be completed – due to COVID -related restrictions, for 
example – at their intended visits may be completed at the subsequent visit (see Appendix B).  
 
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050202] time that the participant ’s parent/guardian is seen in 
person. If th e family has not been seen in person and the participant r eaches 16 years of age, a 
telephone consenting procedure will be used to continue with quarterly phone calls, according to 
IRB requirements. In these cases, written consent will be obtained at the n ext clinic visit , before 
any study activity . We will also obtain written assent from participating children according to 
local IRB guidelines before enrollment into URECA V.  
 14/15 -Year Clinic Visit A  
At the 14/15 -year Visit A, questionnaires about the participant’s physical health, habits, and 
environment will be administered. Questionnaires pertaining to stress and mental health  will 
also be administered . A brief physical examination will be conducted, to focus on ears, nose, 
throat, chest an d skin, and including Tanner staging. Urine and blood samples will be collected, 
supplies and instructions for home dust collection wi ll be distributed , and exhaled nitric oxide will 
be measured . IOS and spi[INVESTIGATOR_10239] . Allergen skin testing to a panel of common 
indoor and outdoor allergens will be performed. Methacholine challenge is planned, with post -
bronchodilator spi[INVESTIGATOR_765917].  
 14/15 -Year Clinic Visit B  
At the 14/15 -year Visit B , questionnaires about the participant’s physical health, habits, and 
environment will be administered. A  brief physical examination will be conducted, to focus on 
ears, nose, throat, chest and skin . Urine samples will be collected for post -menarcheal female 
participants. BIA will be performed to assess adiposity. In addition, the Six -Minute Walk Test will 
be performed to assess fitness. Nasal lining fluid  will be collected in addition to  nasal epi[INVESTIGATOR_15129]. IOS and s pi[INVESTIGATOR_10239]. Participants who were unable to conduct the 
methacholine challenge at Visit A will attempt to conduct the procedure at this visit, again with 
post-bronchodilator spi[INVESTIGATOR_765918] . If the methacholine challenge is not conducted at either Visit A or Visit 
B during this time point, it will be conducted at a separate  visit to occur any time after the 14/15 -
year Visit B.   
 16/17 -Year Clinic Visit A  
At the 16/17 -year Visit A,  questionnaires about the participant’s physical health, habits, and 
environment will be administered. Questionnaires pertaining to stress and mental health will 
also be administered. A  brief physical e xamination will be conducted, to focus on ears, nose, 
throat, chest and skin . Urine and blood samples will be collected.  Spi[INVESTIGATOR_765919]. Supplies and instructions for the home dust collection will be 
provided to the famil ies.  
 16/17 -Year Clinic Visit B  
At the 16/17 -year Visit B, questionnaires about the participant’s physical health, habits, and 
environment will be administered. A brief physical examination will be conducted, to focus on 
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050203] data 
related to study outcomes, and also to continue to engage the family in the study and provide 
informational updates. If the final 16 /17-year visit ( Visit B) has occurred , but the child has not yet 
reached the age of [ADDRESS_1050204] data on respi[INVESTIGATOR_1856], environmental exposures and diet, 
health care utilization,  and medication use. These phone calls will continue many questionnaires 
from the original URECA study , in addition to new questions appropriate for the older age group.  
 Methacholine Challenge Visit  
Participants who  are unable to complete  the methacholine challenge at their 14/15 -year Visit A 
or Visit B  will be asked to come to clini c for a separate visit . During this visit, questionnaires will 
be administered  to assess for changes to the participant’s health and medications. The full set 
of questionnaires for annual clinic visits is  not expected, although some may be administered  if 
previously missed. IOS and Spi[INVESTIGATOR_10239] , followed by [CONTACT_765943]. 
If the participant does not meet criteria to perform the challenge, post -bronchodila tor spi[INVESTIGATOR_765920] , if not previously conducted at the 14/15 -year time 
point . 
 Home Environmental Exposure Evaluation  
At the 16/[ADDRESS_1050205] sample ( refer to the  URECA V Dust Collection Instruction s Handout ). A 
combined dust sample from the participant 's bedroom floor and the participant 's bed will be  
collected. The room where the participant  sleeps most ni ghts will be considered the bedroom. 
Measuring templates will be used to delineate the areas to be vacuumed.  Dust will be collected 
using a vacuum cleaner with a special dust collection filter attached. The dust collector will be 
placed into a sealable pla stic bag and mailed back to the  study center for temporary storage 
(frozen). Crude samples will be batched and shipped to a  central laboratory by [CONTACT_765944], extraction, and analysis. The dust specimens will  be assayed to measure the 
concentr ation allergens  such as : Der p 1, Der f 1, Bla g 1, Bla g 2, Fel d 1, Can f 1, Alt a 1, and 
Mus m 1. Additional allergens of interest and markers of fungal and microbial  exposure may be 
measured.   In addition, the caretaker  or participant  will complete a d ust collection questionnaire, 
which will be  mailed back with the dust collector.   
When problems arise with the family doing the environmental sample collections, staff may go 
to the home to collect the dust samples.  
 Additional Visits or Contacts  
Additional  visits or telephone contacts may be made for any of the following reasons:  
1. A visit was conducted but [ADDRESS_1050206] information needs to be updated (no more often than every 6 months) . 
Any of the assessments listed above may be conducted at additional visits or by [CONTACT_756] (as 
appropriate) —either for the first time or for reassessment.  
During the consent process, the participants will be asked to consent or assent to the possibility 
of additional visits or contacts as described in this section.  No participant will be subjected to an 
assessment for which he or she has not provided written consent or assent, and no informed 
consent/assent form will contain any information that has not b een approved by [CONTACT_50379].  
 Re-contact [CONTACT_765945]/guardian of the participant is asked during the informed consent process to 
indicate that contact [CONTACT_765946].  
8 Assessment of Safety  
 Definition of an Adverse Event (AE)  
The URECA study has been designated as an observational birth cohort study by [CONTACT_765947]. As such, this study involves minimal active intervention outside of the normal standard of 
care for the participant.  No study drugs are used in the URECA study.  Adverse events are 
limited to any occurrence or worsening of an undesirable or unintended sign (including an 
abnormal laboratory finding), symptom, or disease in a study subject that is specifically 
associated (probably, possibly, or definitely – defined in section [IP_ADDRESS]) with a study procedure 
that is not part of the normal standard of care for the participant. In the URECA study, adverse 
events are those related to the blood draws, nasal sample collection, a llergen skin testing, 
sputum collection, or pulmonary function tests not included as part of standard of care for this 
group of patients.  
 Definition of a Serious Adverse Event (SAE)  
A Serious Adverse Event (SAE) is defined as an AE resulting in one of the following outcomes:  
 Death during the period of protocol -defined surveillance  
 Life Threatening Event (defined as an event that places a participant at immediate risk of 
death)  
 Inpatient hospi[INVESTIGATOR_164632] -defined surveillance  
 Congenital anomaly or birth defect  
 Persistent or significant disability/incapacity  
Any other condition which, in the judgment of the investigator, represents a significant hazard, 
such as an important medical event that does not result in one of the above outcomes, may be 
considered a serious adverse event when the event jeopardizes the participant or requires 
medical or surgical intervention to prevent one of the outcomes listed above.  
Childhood  Asthma in Urban Settings  Confidential  Page 26 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  
 Death Not Related to Study Pro cedures  
A death occurring in a study participant not associated with blood draws, nasal sample 
collection, allergen skin testing, sputum collection, or pulmonary function tests will be reported 
as a serious adverse event not related to study procedures. Th e reporting process will follow the 
SAE reporting process.  
 Methods and Timing for Assessing, Recording, Analyzing 
and Adverse Events  
8.4.1  Methods and Timing for Assessment  
[IP_ADDRESS]  Grading of Adverse Events/Serious Adverse Events  
Each adverse event will be assessed for severity and classified into one the categories below:  
 Grade 1 (Mild):  Event requires minimal or no treatment and do not interfere with the 
participant’s daily activities.  
 Grade 2 (Moderate):  Event results in a low level of inconvenience or concern with th e 
therapeutic measures.  Moderate events may cause some interference with functioning.  
 Grade 3 (Severe):  Event interrupts a subject’s usual daily activity or functioning and 
may require systemic drug therapy or other treatment.  Severe events are usually 
incapacitating.  
 Grade 4 (Life threatening):   Any adverse drug experience that places the participant, in 
the view of the investigator, at immediate risk of death from the event as it occurred.  
 Grade 5 (Death)  
[IP_ADDRESS]  Attribution of Adverse Event to Study Procedure  
For the purpose of this study, only AEs related to a study procedure (Section 8.1) will be 
reportable and by [CONTACT_689419]. The degree of certainty about 
relatedness will be graded using the two categories below.  
 Definitely Related:  There is clear evidence to suggest a causal relationship, and other 
possible contributing factors can be ruled out. The clinical event, including an abnormal 
laboratory test result, occurs within a reasonable timeframe after study procedure(s) and  
cannot be explained by [CONTACT_9153].  
 Possibly Related:  There is some evidence to suggest a causal relationship (e.g., the 
event occurred within a reasonable time after study procedure(s)).  However, the 
influence of othe r factors may have contributed to the event (e.g., the subject’s clinical 
condition, other concomitant events). Although an adverse event may be judged only as 
“possibly related” soon after discovery, it can be flagged as requiring more information 
and lat er be upgraded to “definitely related”.  
Childhood  Asthma in Urban Settings  Confidential  Page 27 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  8.4.2  Recording/Documentation  
Adverse events and serious adverse events related to the study procedures will be recorded on 
an appropriate eCRF. The event, the procedure to which it is related, start date, stop date, and 
severity of each reportable event will be recorded on the eCRF.  
8.4.3  Analysis/Management  
The rate of AEs has historically been low in this study; therefore, the primary analysis of AEs will 
occur by [CONTACT_765948] 8.5.  Additional ma nagement is not 
expected to be necessary.  
 Reporting Procedures  
All adverse events related to the blood draws, nasal sample collection, allergen skin testing, 
sputum collection, or pulmonary function tests occurring during the study will be reported to the 
SACCC. The SACCC reports to the NIAID Medical Monitor who is responsible for passing the 
information on to the NIAID Data Safety and Monitoring Board (DSMB). Adverse events will be 
followed until resolved or considered stable.  
8.5.1  Serious Adverse Event Reporti ng 
Adverse event reporting requirements to the NIAID DSMB for this protocol are as follows:  
 Investigators will submit a completed serious adverse event report to the NIAID DSMB 
within [ADDRESS_1050207] death, a potentially life -threa tening 
(Grade 4) serious adverse event that is possibly or definitely related to study 
procedure(s), an urgent inpatient hospi[INVESTIGATOR_765921].  
 Investigators will submit a completed serious adverse event report to the NIAID DSMB 
within 15 days after becoming aware of any Grade 3 (severe) adverse event that is 
possibly or definitely related to study procedure(s), or an inpatient hospi[INVESTIGATOR_059] (other 
than elective), a persistent or significant disability/incapacity, or a congenital 
anomaly/ birth defect.  
 Investigators will report within 15 days on any other event or condition regardless of 
grade, which in their judgment represents an event reportable to the NIAID DSMB.  
 Investigators will forward all safety reports and related communications to the NIAID 
DSMB within 15 days of receipt.  
 A summary of all adverse events will be reported to the NIAID DSMB with a continuing 
review submission.  
8.5.2  Adverse Event Reporting  
Adverse events which are not SAEs or Grade 2 or higher unexpected AEs, will be reco rded on 
the appropriate case report form and sent to the SACCC for incorporation into annual reporting 
to the NIAID and DSMB.  
Childhood  Asthma in Urban Settings  Confidential  Page 28 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  8.5.3  Reporting to the IRB  
The Principal Investigator (or delegate) must report adverse events and serious adverse events 
to the centra l IRB promptly in accordance with local regulations or policies, in addition to 
providing the information to the SACCC.  
8.5.[ADDRESS_1050208]:  a) it is resolved, b) participant is 
stable, or c) a minimum of [ADDRESS_1050209].  
 Participant Discontinuation  
Participants may choose to withdraw from the study at any time, during a study visit, or 
afterwards in person, by [CONTACT_756], or in writing.  
Participants may be prematurely terminate d from the study for the following reasons:  
1. The participant elects to withdraw consent from all future study activities.  
2. The participant is “lost to follow -up” (i.e., no further follow -up is possible because 
attempts to re -establish contact [CONTACT_765949]).  
3. The investigator no longer believes participation is in the best interest of the 
participant.  
Participants will be notified, if possible, if they are discontinued from the study.  No additional 
follow -up will be required.  
 Replacement of  a Participant Who Discontinues Study 
Participation  
URECA study participants will not be replaced after discontinuation. However, “lost” study 
participants who are subsequently relocated and who provide informed consent, may be re -
activated.  
Childhood  Asthma in Urban Settings  Confidential  Page 29 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  9 Clinical Monit oring Structure  
 Site Monitoring Plan  
Clinical site monitoring will be conducted according to the URECA Clinical Monitoring Plan 
(CMP) for ICAC -[ADDRESS_1050210] protection, study procedures, and laboratory 
and data collection processes are of  high quality and meet sponsor, International Conference on 
Harmonisation, Good Clinical Practice, and regulatory guidelines.  Representatives from the 
National Institute of Allergy and Infectious Diseases (NIAID) and/or the SACCC will visit each 
clinical site or meet with each clinical site via telephone during a specified timeframe according 
to the URECA CMP for ICAC -07. Key study personnel must be available to assist the visitors 
during these visits or attend the call if completed via telephone.  Additio nal details regarding 
clinical site monitoring, including remote monitoring, are outlined in the URECA CMP and MOP 
for ICAC -07. 
 Safety Monitoring  
Safety monitoring will be performed following the URECA Safety Management Plan (SMP).  
9.2.[ADDRESS_1050211] quarterl y. 
9.2.2  DSMB Review  
The DSMB will review any events as requested by [CONTACT_32366], SACCC, or DAIT Medical 
Monitor. They will review a listing of all adverse events once per year. Further, the DSMB will be 
informed of expedited SAEs at the same time as the c entral IRB.  
10 Statistical Considerations  
 Overview  
The URECA continuation in to age 17 years has the following specific aims that will be 
accomplished under this protocol. Mechanistic and substudy aims will be addressed in separate 
analytic plans.  
1. To determin e the wheezing, asthma and atopy phenotypes in minority children growing 
up in poor urban neighborhoods as they develop from birth through adolescence.  
2. To longitudinally analyze the development of lung function and its relationship to asthma.  
3. To identify which urban exposures (allergens, pollutants, microbes, viral infections, 
stress) from early life onward affect the development and natural history through 
adolescence of asthma, allergic rhinitis and allergic sensitization.  
4. To determine the association o f pre-pubertal obesity and the effect of pubertal changes 
in adiposity and sex hormones on lung growth and asthma onset, prevalence and 
morbidity.  
Childhood  Asthma in Urban Settings  Confidential  Page 30 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  
 Endpoints  
10.2.1  Primary Endpoints  
The primary endpoints for this phase of the URECA study are wheezing, asthma and atopy 
phenotypes in minority children.  
10.2.2  Secondary Endpoints  
Secondary endpoints include:  
1. Methacholine responsiveness – this will be ascertained at age 14/15.  
2. Pulmonary function – pre- and post - bronchodilator spi[INVESTIGATOR_765922] 14/15, and once at age 16/17.   
3. Allergic sensitization – defined as a dichotomous variable (aeroallergen -specific IgE 
by [CONTACT_765936]) or as a continuum (number of positive skin or sIgE tests, 
sum of sIgE values).  
4. Allergic rhinitis – chronic seasonal or perennial rhinitis and corresponding allergen -
specific IgE or skin test.  
 Measures to Minimize Bias  
The primary threat to validity in a cohort study such as URECA is missing data due to loss -to-
follow -up or missed visits and procedures. The URECA study to date has done a remarkable job 
of retaining the participants, with 73% of the original cohort still active at age 14/15. In recent 
phases of URECA, >85% of expected visits have been completed.  
Missing data create problems because fewer observations will reduce the power of the study. If 
the data are nonrandomly missing,  i.e. associated with either the predictor or the outcome,  
estima tes generated in the analyses may be biased, possibly leading to invalid inferences. For 
example, children with asthma symptoms might miss their spi[INVESTIGATOR_765923]. This can 
lead to nonrandomly missing data and can complicate analyses.   
The pattern of missing data  will be explored for every analysis.  Missing data can generally be 
characterized as being in 1 of 3 classes --missing completely at random, missing at random, and 
not missing at random (also called nonignorably missing or informatively missing) .11-[ADDRESS_1050212] and environment al microbiota.  
Using the extensively and longitudinally characterized URECA cohort, we will:  
1. Categorize URECA subjects into already described early life patterns of wheezing 
(Tucson Children’s Respi[INVESTIGATOR_765924], Avon Longitudinal Study of Parents and 
Children, Prevention and Incidence of Asthma and Mite Allergy ) and development of 
atopic disorders (Manchester) to determine if these patterns are indeed observed 
among inner -city American children.  
2. Using longitudinal data obtained from the URECA cohort throug h the age of [ADDRESS_1050213] on the development and 
maintenance of asthma through the teen years. In particular, symptoms, 
exacerbations, allergy, immunologic measures, BMI, fitness, psychosocial factors 
and objective measu rements of lung function, spi[INVESTIGATOR_038], eNO and IOS will define 
clusters of asthma phenotypes based on a combination of these variables.   We will 
consider latent class analysis and other clustering techniques to identify phenotypes 
in URECA V.  
10.4.2  Analysis of Se condary Objectives  
[IP_ADDRESS]  Early life exposure to household allergens  
To determine whether early life exposure to allergens in the home in the absence of a diverse 
microbiome is associated with sensitization to those allergens and respi[INVESTIGATOR_1856] 
(perennial r hinitis and allergic asthma phenotypes), we will examine the association between 
early -life exposures to allergens and diversity in the microbiome towards allergic sensitization. 
The assumption is that children with high levels of exposure and low microbio me diversity will 
have a higher likelihood of early sensitizations. Early sensitizations will be obtained by [CONTACT_765950]. Then 
a multinomial logit model, with possible adjus tments for race and gender, will test the 
(multiplicative & additive) interaction between these two predictors and the likelihood of early 
sensitization. Furthermore, these prolonged exposures can have a compound effect in 
sensitization, and summary measur es such as cumulative exposures may not fully capture 
these relationships. We proposed to extend the model suggested above by [CONTACT_2329] a distributed 
lag linear (and non -linear) model with flexible exposure -response and lag -response functions to 
examine the as sociation between sensitization and exposures in early life.  
Pathway analysis will be used to determine how a host of environmental factors contribute to 
the development of rhinitis with specific classifications. Based on medical evidence in the 
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050214] a conceptual model to describe how different risk 
factors domains (i.e. allergic inflammation, pulmonary physiology, environmental exposures, 
etc.) are linked to rhinitis. A casual network analysis will be implemented us ing structural 
equations models to simultaneously perform (1) a confirmatory factor analysis in each domain to 
estimate the relationship between the domain of interest and each observed variable used to 
measure the domain and (2) a series of regression mod els to estimate the standardized direct 
effect of each independent domain onto rhinitis.  
[IP_ADDRESS]  Effect of pubertal changes in adiposity and sex hormones 
on lung growth and asthma onset, prevalence and 
morbidity  
Levels of steroid hormones, steroid binding proteins , leptin, adiponectin and serum inflammatory 
indicators (IL -6, TNF -α, CRP) at 8, 10, 12, 14/15, and 16/[ADDRESS_1050215] -pubertal girls and boys. Body habitus and measurements of fitness 
(6-minute walk in clinic) will also be compared among children with vs. without asthma. We 
expec t that children at greatest risk for asthma will be those with low fitness and activity, high 
BMI, increased serum inflammatory markers, and atopy.  
We will use trajectory analysis to examine whether changes in weight or BMI are related to 
asthma prevalence  in children from age 10  to 17 years. We will use semiparametric mixture 
modeling —which combines latent growth curve and mixture modeling —to identify growth 
trajectories over time separately for boys and girls. Trajectory parameters will be estimated 
using  the maximum likelihood approach built upon a binary logit model, using the BIC (Bayesian 
information criterion) to identify the best model. The objective of model selection is to 
summarize the distinctive features as parsimoniously as possible. The result ing growth 
trajectories will be used as predictor variables in a logistic regression model predicting 
development of asthma. The model will be tested for effect modification by [CONTACT_4321].  
10.4.3  Analysis of Exploratory Endpoints  
The overall approach to identify phenoty pes will be similar to that used with the 7 -year and 10 -
year data sets, using latent class mixed models to identify homogenous subpopulations within 
sets of longitudinal variable trajectories. Variables characterizing the trajectory clusters (e.g. 
symptoms , allergic sensitization, lung function and BMI) and other relevant predictors (including 
demographics) will be used to represent subjects in a Gower distance matrix, which can handle 
mixed data types. The Akaike information criterion will be used to selec t the number of clusters 
(i.e. number of subpopulations) for each variable.  These variables will be evaluated for 
collinearity and variable sets that are highly collinear will be represented by a constituent 
variable that is most representative of each su bset. Children will be clustered to identify distinct 
phenotypes selected using four criteria: 1) a generalization of the within -clusters sum of squares 
measure, 2) average silhouette width, 3) Dunn index, and 4) the ratio of average -within versus 
average -between clusters. In this aim, we will identify asthma endotypes by [CONTACT_765951][INVESTIGATOR_765925], including the patterns of airway epi[INVESTIGATOR_765926] [ADDRESS_1050216] an analysis to identify gene expression patterns and 
Childhood  Asthma in Urban Settings  Confidential  Page 33 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  methylation patterns (from ages 11 and 15), and en vironmental exposures that are 
characteristic of each phenotype and distinguish among them.   
To identify endotypes , we will use a sparse multinomial logistic regression model Variables for 
these models include the DNA methylation and expression modules (A im 1), and environmental 
exposures (e.g. viral infections, allergens, microbes, tobacco smoke). Thus, the model will 
represent endotypes by [CONTACT_95559][INVESTIGATOR_765927]. In a sparse model, the learning a lgorithm is biased towards selecting a relatively 
small number of variables. Thus, although we will include a moderately large number of 
candidate variables in the models, only a sufficient number of variables to distinguish the 
phenotypes are selected. We  will use well established sparse learning methods, such as 
LASSO and elastic net, which are well suited to high -dimensional data sets that include many 
potentially irrelevant variables.  
We will next identify biomarkers for predicting respi[INVESTIGATOR_765928] [ADDRESS_1050217] will 
exhibit. Sparse multinomial logistic regression models will be used to evaluate early life 
biomarkers. The candidate predictor variables for these models will include (i) demographics, (ii) 
clinical variables such as wheeze frequency, (iii) gene expression measurements from nasal 
epi[INVESTIGATOR_1663], and (iv) DNAm measurements from nasal epi[INVESTIGATOR_1663].  Aside from 
demographics, these variables will come from measurements taken during the first three y ears 
of life . 
 Sample Size Considerations  
The sample size for the URECA cohort is determined by [CONTACT_765952], and retention 
to this point (442 subjects at age 14 years, which represents 73% of the original 609 recruited 
subjects) has been excell ent. This sample size enabled identification of phenotypes at 7 and 10 
years of age.  
11 Quality Control and Quality Assurance  
Training of study staff will be conducted prior to beginning any new procedures.  All staff 
members will be required to complete cert ification and quality control in all applicable study 
procedures as outlined in the URECA V MOP for ICAC -07.  The site principal investigator [INVESTIGATOR_393353](s) will be responsible for ensuring that all procedures are performed according 
to the proto col. Periodic reviews of procedures will be conducted by [CONTACT_765953].  Details of the quality  control plan, including 
certifications and quality control of study procedures, are provided in the URECA V MOP for 
ICAC -07. 
Childhood  Asthma in Urban Settings  Confidential  Page 34 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  12 Ethics/Protection of Human Subjects  
 The Belmont Report  
In accordance with the FWA00005897 : “This institution assures that all of its activities related to 
human subject research, regardless of funding source, will be guided by [CONTACT_765954].”  Additionally,  the investigator assures that all activities of this protocol will 
be guided by [CONTACT_754099], 45 CFR 46 and all of its subparts (A, 
B, C and D).  
 Institutional Review Board  
A copy of the protoc ol, informed consent forms, other information to be completed by 
[CONTACT_4317], such as survey instruments or questionnaires, and any proposed advertising/ 
recruitment materials will be submitted to the IRB for written approval.  
All subsequent amendments to  the protocol, informed consent documents, and other study 
documentation referenced above must be reviewed and approved by [CONTACT_429318].  The annual Continuing Review must also be reviewed and approved by [CONTACT_765955].  
The IRB will be notified of SAEs and protocol violations.  
 Informed Consent Process  
The informed consent and assent forms are a means of providing information about the study to 
a prospective participant/guardian to allow for an informed decisio n about participation in the 
study. The parent or legal guardian of the participating child (or their legally acceptable 
representative) must read, sign, and date the informed consent form before continuing the study 
or undergoing any study -specific assess ments. Consent materials for participants who do not 
speak or read English will be translated into Spanish for clinical sites with Spanish -speaking 
staff.  
The informed consent and assent forms will be revised whenever important new safety 
information is av ailable, whenever the protocol is amended with changes that require re -
consent/re -assent by [CONTACT_4317], and/or whenever any new information becomes available that 
may affect participation in the study.  
A copy of the informed consent form (and assent form , if applicable) will be given to a 
prospective participant/caretaker for review. The prospective participant/caretaker will be told 
that being in the study is voluntary and that he or she may withdraw from the study at any time 
for any reason.  
 Assent Proc ess 
All URECA V participants  will sign a written assent form as described above.  
 Participant Confidentiality  
Following Health Insurance Portability and Accountability Act guidelines, a participant’s privacy 
and confidentiality will be respected throughout the study.  Each participant will be assigned a 
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050218] by [CONTACT_3486], their staff, 
and the sponsor(s) and their agents. This co nfidentiality is extended to cover testing of biologic 
samples in addition to the clinical information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No in formation concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor.  
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required t o be maintained by [CONTACT_093], including but not limited to medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) for the participants in this study. The clinical site will permit 
access to such records.  
 Study Discontinuation  
There are no study halting rules . However, the study may be discontinued at any time at the 
discretion of the NIH.  
[ADDRESS_1050219] Keepi[INVESTIGATOR_765929] a login -secured, web -based electronic data capture (EDC) system. 
The system operates on all Internet browser p latforms and is designed to handle numerous 
simultaneous studies within a program. Physical, logical, and operational security related to the 
data is implemented by a network operation center. Additional details regarding the EDC system 
are provided in the  Data Management Plan (DMP) for ICAC -07. 
 Data Management Responsibilities  
The data management tasks required for this study are a joint responsibility of the SACCC and 
clinical site staff. The clinical site staff are responsible for collecting and entering  study data into 
the EDC system per the protocol and specific guidelines in the URECA V MOP for ICAC -07, for 
ensuring the accuracy of these data, and for maintaining and organizing all original source 
documents and any additional sources of data. The EDC s ystem has been validated and is 
compliant with Part [ADDRESS_1050220], a laboratory or clinical report, a paper 
CRF, or an eCRF.  
The details regarding the electronic verification of all data fields, including univariate and 
multivariate validation (i.e., range checks and cross -field and cross -form checks), validation of 
data omission, and query management are listed in the DMP.  
 Types of Data  
Clinical, demographic, labo ratory, and AE data will be collected for this study.  
 Source Documents and Access to Source Data/Documents  
The clinical sites participating in this study will maintain the highest degree of confidentiality 
permitted for the clinical and research informatio n obtained from the participants. Medical and 
research records will be maintained at each clinical site in the strictest confidence. However, as 
a part of the quality assurance and legal responsibilities of an investigation, the clinical site must 
permit a uthorized representatives of the sponsor to examine (and when required by [CONTACT_117574], to copy) clinical records for the purpose of quality assurance reviews, audits, and 
evaluations of the study safety and progress. Unless required by [CONTACT_765956], only the coded identity associated with documents or with other participant data may 
be copi[INVESTIGATOR_530] (and all personally identifying information must be obscured). Authorized 
representatives as noted above are bound to maintain the strict  confidentiality of medical and 
research information that is linked to individuals. The clinical site will normally be notified before 
auditing visits occur.  
 Timing/Reports  
Data will be monitored by [CONTACT_765957]. Status reports on the progress of the  study and 
data collection will be generated regularly. Reports will be sent to the NIAID project manager 
and medical officer on a regular basis.  
 Study Records Retention  
Study documents must be maintained at the clinical site or a local storage facility fo r at least [ADDRESS_1050221] copi[INVESTIGATOR_3110], IRB approval documentation and related correspondence, and signed 
informed consent forms.  
14 Publication Policy  
Presentations and publication of the results of this study will be governed by [CONTACT_765958].  
  
Childhood  Asthma in Urban Settings  Confidential  Page 37 of 40 
 
URECA V  Protocol  Version 30.0  21 January 2021  Appendix A: Scientific References  
1. Gern JE. The Urban Environment and Childhood Asthma study. J Allergy Clin Immunol 
2010;125:545 -9. 
2. Gern JE, Visness CM, Gergen PJ,  Wood RA, Bloomberg GR, O'Connor GT, et al. The 
Urban Environment and Childhood Asthma (URECA) birth cohort study: design, 
methods, and study population. BMC Pulm Med 2009;9:17.  
3. Zook PM, Jordan C, Adams B, Visness CM, Walter M, Pollenz K, et al. Retention 
strategies and predictors of attrition in an urban pediatric asthma study. Clin Trials 
2010;7:400 -10. 
4. O'Connor GT, Lynch SV, Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early -
life home environment and risk of asthma among inner -city children. J Alle rgy Clin 
Immunol 2018;141:1468 -75. 
5. Bacharier LB, Beigelman A, Calatroni A, Jackson DJ, Gergen PJ, O'Connor GT, et al. 
Longitudinal Phenotypes of Respi[INVESTIGATOR_765930] a High -Risk Urban Birth Cohort. Am J 
Respir Crit Care Med 2019;199:71 -82. 
6. Demoly P, Pi[INVESTIGATOR_765931] e V, Bousquet J. In vivo methods for the study of allergy. In: Adkinson 
NFJ, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, eds. 
Middleton's Allergy: Principles and Practice. Philadephia: Mosby; 2003:631 -55. 
7. Silkoff PE, McClean PA, Slutsky AS,  Furlott HG, Hoffstein E, Wakita S, et al. Marked 
flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric 
oxide. Am J Respir Crit Care Med 1997;155:[ADDRESS_1050222] of Directors, July 1999. Am J Respi r Crit Care 
Med 1999;160:2104 -17. 
9. Fahy JV, Boushey HA, Lazarus SC, Mauger EA, Cherniack RM, Chinchilli VM, et al. 
Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter 
study. Am J Respir Crit Care Med 2001;163:1470 -5. 
10. American Thoracic Society. ATS statement: guidelines for the six -minute walk test. Am J 
Respir Crit Care Med 2002;166:[ADDRESS_1050223] NM. Missing data in longitudinal studies. Statistics in medicine 1988;7:305 -15. 
12. Little RJA. Modeling the drop -out mechanism i n repeated -measures studies. Journal of 
the American Statistical Association 1995;90:1112 -21. 
13. Little RJA, Rubin DB. Statistical Analysis with Missing Data. [LOCATION_001]: Wiley; 1987.  
14. Bowman FD, Stewart PW, Sen PK, Helms RW. Making inferences about projected 
completors in longitudinal studies. Journal of biopharmaceutical statistics 2004;14:[ADDRESS_1050224] MG. Informative Drop -Out in Longitudinal Data Analysis. Applied 
Statistics 1994;43:[ADDRESS_1050225] NM, Rubin DB. Multiple Imputation in Mixtu re Models for Nonignorable 
Nonresponse With Follow -ups. Journal of the American Statistical Association 
1993;88:984 -93. 
17. Schluchter MD. Methods for the analysis of informatively censored longitudinal data. 
Statistics in medicine 1992;11:1861 -70. 
18. Wu MC, Bail ey KR. Estimation and comparison of changes in the presence of 
informative right censoring: conditional linear model. Biometrics 1989;45:939 -55. 
19. Wildasin HA, Wallace D, Kesler K. Assessing Dropout Bias with Mixed -Effects and 
pattern Mixture Models.  28th A nnual Meeting of the Society for Clinical Trials; 2007 May 
2007; Montreal, Canada.  
  
Childhood  Asthma in Urban Settings  Confidential  Page [ADDRESS_1050226] -Bronchodilator IOS/Spi[INVESTIGATOR_765932] -
Bronchodilator IOS/Spi[INVESTIGATOR_765933].  